Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.43
Bid: 18.92
Ask: 19.94
Change: 0.00 (0.00%)
Spread: 1.02 (5.391%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.43
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BATM expands COVID-19 diagnostic tests

15 Jul 2020 07:00

RNS Number : 0092T
BATM Advanced Communications Ld
15 July 2020
 

LEI: 213800FLQUB9J289RU66

15 July 2020

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

BATM expands COVID-19 diagnostic tests

Launch of three new test kits to advance the diagnosis of COVID-19 and other respiratory illness

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces the launch of three new diagnostic kits to significantly advance the diagnosis of COVID-19 and other respiratory illnesses.

 

Highlights

· COVID-19 serologic test upgraded to measure the quantity of antibodies in the blood rather than just the presence or absence

· COVID-19 antigen test upgraded to detect spike (S) gene to enable diagnosis of COVID-19 in people with low viral loads, increasing testing accuracy

· New molecular diagnostics test developed to rapidly identify the specific respiratory virus or bacteria in someone presenting with symptoms of, or suspected to have pre-symptomatic respiratory illness

 

The Group expects to commence sales and production of the kits at its Adaltis facility in Italy at the end of Q3/beginning of Q4 2020.

 

COVID-19 serologic test

 

The Group's serologic test for the detection of COVID-19 antibodies, as announced on 5 May 2020, has been advanced to be able to measure the quantity of antibodies in the blood rather than just identifying their presence or absence (qualitative test). The upgraded test measures both IgM antibodies, which are produced a few days after infection and remain in the blood for a short period, and IgG antibodies, which are longer-term (produced a few days after infection and remain in the blood for a few months) antibodies. It has the same levels of sensitivity and specificity as those of the market-leading brands, with sensitivity of 100.0% and specificity of 99.8%.

 

This upgraded test was developed by the Group in response to the growing amount of medical research suggesting that the volume of antibodies in the blood of someone who has recovered from COVID-19 is low and declines. This test is designed to support public health authorities and individuals in making informed decisions by knowing the potential level of immunity based on the volume of antibodies detected and their deterioration over time. As such, it is an important tool for estimating herd immunity and the efficiency of future vaccines.

 

This kit will run on Adaltis instruments as well as on any standard ELISA instrument.

 

COVID-19 antigen test

 

The Group has expanded the gene discovery capability of its COVID-19 antigen test to five and, importantly, to include the spike (S) gene. The S gene is the protein that the virus uses to invade human cells. It is present in a person's blood even if they have a very low viral load of COVID-19 (which might otherwise go undetected). As a result, by being able to detect the S gene, this test can provide more accurate results, reducing the risk of false positives and false negatives.

 

Reducing false negative results will prevent missing real cases, especially those in the early stages of infection, who could unknowingly spread the infection. At the same time, reducing false positive results will avoid the needless quarantining of people who have not actually been infected.

 

The five gene discovery capability compares with a market standard of one to three gene discovery capability. This kit can run on Adaltis instruments as well as on any standard PCR instrument.

 

New molecular diagnostics test

 

The Group has launched a new molecular diagnostics kit that is able to test for multiple respiratory pathogens at the same time. In less than an hour, it can identify the particular cause (pathogen) of a respiratory illness, enabling the correct treatment or action to be rapidly implemented. It can identify and differentiate between all prominent respiratory viruses, including all strains of COVID-19, flu and the common cold. It can also detect the bacteria that cause the serious pulmonary illnesses that are believed to be a secondary infection of COVID-19, such as pneumonia and Legionnaires' disease. This new kit was developed in collaboration with academics at Tor Vergata University in Italy.

 

The ability to rapidly identify the specific cause of a disease enables the correct treatment to be given more quickly resulting in better patient outcomes. This is particularly important for the coming winter where seasonal colds and flu could appear alongside COVID-19 and patients would present with similar symptoms, with cases already on the rise in parts of the southern hemisphere where winter has begun. The ability to rapidly diagnose the particular illness would help to alleviate some of the heavy strain on the public health systems.

 

This kit, which is expected to receive CE certification in the coming weeks, can run on all Adaltis instruments as well as on any standard PCR instrument. Further information on the detected viruses are listed in the Notes to Editors below.

 

Dr. Zvi Marom, Chief Executive Officer of BATM, said: 

 

"I am delighted to be introducing these three new diagnostic kits that place us at the forefront in the fight against COVID-19. Accurate diagnostics is the only tool that exists that can enable a transition towards normality as we continue to live in the presence of the pandemic. We believe that our new kits can provide a vital resource for public health authorities and we are greatly encouraged that we have already received requests to receive these tests immediately once released.

 

"I would like to give thanks to our dedicated workforce who do all that is humanly possible to develop industry-leading diagnostic solutions. In particular, special thanks goes to our R&D teams led by Prof. Favaro and Drs. Mattina, Padula and Deangelo, as well as the support team led by Mr. Middleton. Together with those who work on longer term R&D strategy and our partners, they have been able to translate scientific knowhow into real-world products that are being used every day to support public health authorities and their communities in these distressing times."

 

 

Enquiries:

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

 

Notes to Editors

 

Viruses detected by new molecular diagnostics test

 

The Group's new molecular diagnostics kits is able to detect all strains of COVID-19 (229E, HKU1, NL63, OC43) as well as all common respiratory viruses including Flu A&B, RSV A&B (common cold), Adeno Virus, Meta Pseudo Virus and Roca Virus.

 

It can also detect the bacteria that cause serious pulmonary illnesses as a secondary infection of COVID-19, including Bordetella Pertussis, Legionella pneumophila, Mycoplasma pneumonia and Chlamydiophila pneumonia.

 

Antibodies and antigens

 

Antibodies are proteins produced by the body in response to harmful substances called antigens (e.g. a virus). ELISA (enzyme-linked immunosorbent assay) serological tests measure the amount of various antibodies present in the blood when the body is responding to a specific infection, like COVID-19. The ELISA serological test detects the body's immune response to the infection caused by the virus rather than detecting the virus itself - to help identify those who have been infected and developed antibodies that may protect them from future infection. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PRLBIGDRLSBDGGS
Date   Source Headline
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review
14th Apr 20229:30 amRNSAnnual Financial Report
13th Apr 20227:00 amRNSAppointment of Non-Executive Director
4th Apr 20227:00 amRNSTransaction in Own Shares and TVR
18th Mar 20227:00 amRNSStrategic Partnership for Edgility with NEXCOM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.